| Adlyxin (lixisenatide) / Sanofi |
NCT02020629: Study on Lixisenatide and Counterregulation to Hypoglycemia |
|
|
| Completed | 4 | 18 | Europe | Lixisenatide, Lyxumia | Lund University | Type 2 Diabetes | 08/14 | 08/15 | | |
| Completed | 4 | 404 | Europe | liraglutide, lixisenatide | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 11/14 | 11/14 | | |
NCT02200991: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine |
|
|
| Completed | 4 | 136 | Japan | LIXISENATIDE AVE0010, Sitagliptin, Januvia, Insulin glargine HOE901, Lantus | Sanofi | Type 2 Diabetes Mellitus | 11/15 | 11/15 | | |
| Completed | 4 | 8 | Europe | Lixisenatide, GLP-1 agonist, Lyxumia, Placebo | University of Surrey, Sanofi | Type 2 Diabetes | 01/16 | 01/16 | | |
| Completed | 4 | 40 | Europe | Lixisenatide, Lyxumia, Insulin glulisine, Apidra | Amsterdam UMC, location VUmc | Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus, Glucagon-Like Peptide 1 | 04/16 | 04/16 | | |
NCT02767596: Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog |
|
|
| Terminated | 4 | 2 | RoW | Lixisenatide, Lyxumia, Basal insulins, Glargine, Detemir, Degludec | Laniado Hospital | Diabetes Mellitus Type 2 | 02/17 | 02/17 | | |
